Gatipotuzumab
(Synonyms: PankoMab) 目录号 : GC69153Gatipotuzumab是一种人源化单克隆抗体，特异性靶向Delta样配体3（DLL3）蛋白，可识别黏蛋白-1 的肿瘤特异性表位 (TA-MUC1)，具有潜在的抑制癌症发展的功能。
Cas No.:1264737-26-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Gatipotuzumab is a humanized monoclonal antibody that specifically targets the tumor-associated mucin-1 (TA-MUC1) epitope and has the potential to inhibit cancer progression[1]. DLL3 demonstrates high expression levels in small cell lung cancer (SCLC) and other neuroendocrine tumors, while showing minimal expression in normal tissues. This selective targeting mechanism enables Gatipotuzumab to deliver cytotoxic agents specifically to cancer cells expressing DLL3, thereby minimizing impact on healthy cells[2-3]. Further exploration is underway to investigate its potential utility in treating other DLL3-expressing neuroendocrine tumors[4].
Gatipotuzumab (0, 30, 60µg/mL) treatment of ovarian cancer cells (COV318, OV-90, OVCAR-3, SKOV-3) significantly reduced cell viability, as evidenced by decreased cell proliferation. Moreover, co-treatment of ovarian cancer cells with Gatipotuzumab (60µg/mL) and 4-hydroxy-tamoxifen (4-OHT, 5µM) further decreased cell viability at 48 and 72 hours, with a more pronounced effect than treatment with Gatipotuzumab or 4-OHT alone[5].
References:
[1] Ochsenreither S, Fiedler WM, Conte GD, et al. Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors. ESMO Open. 2022 Apr;7(2):100447.
[2] Owen DH, Giffin MJ, Bailis JM, et al. DLL3: an emerging target in small cell lung cancer. J Hematol Oncol. 2019 Jun 18;12(1):61.
[3] Heublein S, Page S, Mayr D, et al. Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer. Int J Mol Sci. 2019 Jan 12;20(2):295.
[4] Heublein S, Friese K, Kost B, et al. TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer. J Cancer Res Clin Oncol. 2018 Oct;144(10):1899-1907.
[5] Heublein S, Page S, Mayr D, et al. Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer. Int J Mol Sci. 2019 Jan 12;20(2):295.
Gatipotuzumab是一种人源化单克隆抗体，特异性靶向Delta样配体3（DLL3）蛋白，可识别黏蛋白-1 的肿瘤特异性表位 (TA-MUC1)，具有潜在的抑制癌症发展的功能[1]。DLL3在小细胞肺癌（SCLC）和其他神经内分泌肿瘤中高表达，但在正常组织中表达极少。这种选择性靶向使Gatipotuzumab能够将细胞毒性药物特异性地传递给表达DLL3的癌细胞，从而减少对健康细胞的影响[2-3]。此外，Gatipotuzumab还在探索其在其他表达DLL3的神经内分泌肿瘤中的潜在应用[4]。
Gatipotuzumab（0、30、60µg/mL）处理卵巢癌细胞（COV318、OV-90、OVCAR-3、SKOV-3），显著降低了细胞的活性和增殖能力。此外，Gatipotuzumab（60µg/mL）与4-Hydroxytamoxifen（4-OHT，5µM）联合处理的卵巢癌细胞，在48小时和72小时后，细胞活性进一步降低，且这种降低效果比单独使用Gatipotuzumab或4-OHT更为显著[5]。
| Cell experiment [1]: | |
Cell lines | Ovarian cancer cells (COV318, OV-90, OVCAR-3, SKOV-3) |
Preparation Method | The ovarian cancer cells were inoculated into 96-well plates at a density of 3000 cells per well and cultured until they reached the logarithmic phase of growth. The cells were then treated with different concentrations of Gatipotuzumab and/or 4-Hydroxy-Tamoxifen (4-OHT) for 48 and 72 hours. |
Reaction Conditions | 0, 30, 60µg/mL Gatipotuzumab; 0, 5µM 4-OHT; 48 and 72 hours of treatment |
Applications | Gatipotuzumab treatment significantly reduced cell viability, as evidenced by decreased cell proliferation. Co-treatment of ovarian cancer cells with Gatipotuzumab (60µg/mL) and 4-OHT (5µM) further decreased cell viability at 48 and 72 hours, with a more pronounced effect than treatment with Gatipotuzumab or 4-OHT alone. |
[1] Heublein S, Page S, Mayr D, et al. Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer. Int J Mol Sci. 2019 Jan 12;20(2):295. | |
| Cas No. | 1264737-26-9 | SDF | Download SDF |
| 别名 | PankoMab | ||
| 分子式 | 分子量 | ||
| 溶解度 | 储存条件 | Store at -20°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
-
Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet